

Dr Reddy's' Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~\$300mn). However, assuming muted growth in the company's base oncology portfolio since FY22, gRevlimid contribution would have been higher by ~\$100mn in FY26 vs our base case. We have maintained the view that the debate around the magnitude of the Semaglutide opportunity for Dr Reddy's (please connect with us for our detailed assumptions) is only meaningful if the ex-gRevlimid US base settles at ~\$900mn-\$1bn. To that extent, we now have greater clarity around the FY26 US base business levels (lower bound closer to \$900mn) even as our and the street's gRevlimid EBITDA contribution assumptions for FY26 might still prove to be conservative. Besides, price erosion in global generics in FY26 remained in the high single digit. We argue for measured optimism around an on-time approval for Abatacept (IV US launch base case - 4QFY27), given that a majority of the past CRLs issued by the USFDA to first biosimilar filers cited facility-linked queries (Exhibit 1) and Dr Reddy's' Bachupally facility has faced repeated challenges in meeting the FDA's expectations over the last 3 years (US CMO option more likely for the subcutaneous filing). Note that even the company's partnered biosimilar filings such as Denosumab have faced a similar set of challenges (delayed by a year vs the company's initial expectations). We roll forward to Jun-28E EPS and revise up our TP by 8.3% to Rs1,300 from Rs1,200 earlier; retain REDUCE.

Bachupally has faced repeated challenges in meeting the FDA's expectations

The Bachupally biologics facility has undergone three FDA inspections over the last 3 years (Oct-23, Sep-25, Jun-26). The first inspection was a pre-license inspection (PLI) for Rituximab which resulted in 9 Form-483 observations. A reinspection conducted in Sep-25 resulted in 5 Form-483 observations, with the FDA noting that CAPAs implemented in response to observation 2 from the Oct-23 inspection could not be adequately assessed. Note that Rituximab was expected to be launched in FY25. While Abatacept has been filed from a separate block and the company is confident of addressing the 7 observations issued post the recent PLI, we note that a majority of the past CRLs issued by the FDA to first biosimilar filers cited facility-linked queries (Exhibit 1), with some filers also receiving multiple CRLs.

Partnered biosimilar filings have faced a similar set of challenges

Alvotech, Dr Reddy's' partner for Denosumab, had received a CRL in Jan-26 following a PLI of Alvotech's Reykjavik facility. Alvotech undertook remediation and following a reinspection in May-26, which concluded with observations that the company characterized as addressable, announced its intent to resubmit the BLA for Denosumab with an approval now expected in CY26 (delayed by a year vs Dr Reddy's' initial expectations).

Target Price – 12M	Jun-27
Change in TP (%)	8.3
Current Reco.	REDUCE
Previous Reco.	REDUCE
Upside/(Downside) (%)	(4.2)

Stock Data	DRRD IN
52-week High (Rs)	1,415
52-week Low (Rs)	1,148
Shares outstanding (mn)	834.7
Market-cap (Rs bn)	1,133
Market-cap (USD mn)	11,966
Net-debt, FY27E (Rs mn)	(26,944.8)
ADTV-3M (mn shares)	2.2
ADTV-3M (Rs mn)	3,402.1
ADTV-3M (USD mn)	35.9
Free float (%)	73.1
Nifty-50	23,865.8
INR/USD	94.7


Shareholding, Mar-26

Promoters (%)	26.6
FPIs/MFs (%)	21.1/42.7

Price Performance

(%)	1M	3M	12M
Absolute	4.1	8.1	5.8
Rel. to Nifty	2.7	1.2	13.1

1-Year share price trend (Rs)



Dr Reddy's: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	324,269	340,463	370,451	403,750	443,647
EBITDA	85,452	74,772	74,514	87,246	103,212
Adj. PAT	56,672	50,293	44,880	54,292	66,325
Adj. EPS (Rs)	68.3	60.6	54.1	65.4	79.9
EBITDA margin (%)	26.4	22.0	20.1	21.6	23.3
EBITDA growth (%)	9.0	(12.5)	(0.3)	17.1	18.3
Adj. EPS growth (%)	1.8	(11.3)	(10.8)	21.0	22.2
RoE (%)	18.5	14.2	11.3	12.3	13.4
RoIC (%)	21.0	13.5	10.7	12.2	13.9
P/E (x)	19.9	22.4	25.1	20.7	17.0
EV/EBITDA (x)	12.5	14.2	14.3	12.2	10.3
P/B (x)	3.4	3.0	2.7	2.4	2.2
FCFF yield (%)	(5.5)	0.8	2.1	2.6	3.3

Source: Company, Emkay Research

Shashank Krishnakumar

shashank.krishnakumar@emkayglobal.com
+91-22-66242466

Mohd Suheb Alam


suheb.alam@emkayglobal.com
+91-22-66242413

Exhibit 1: A majority of the past CRLs issued by the USFDA to first biosimilar filers cited facility-linked queries

Innovator	Brand Name	Product	First filer	Filing Date	Approval Date	Marketing Date	Queries raised in the CRL	CRL Issue Date	BLA Resubmission Date
Genentech and Biogen	Rituxan	Rituximab	Celltrion/ Teva	Apr-17	Nov-18	Nov-19	Filing impacted by issues identified at Celltrion’s manufacturing facility in South Korea	Feb-18	May-18
Genentech	Actemra	Tocilizumab	Fresenius Kabi	May-22	Mar-24	Apr-24	Outstanding facility inspection deficiencies	May-23	Sep-23
Sanofi	Lantus	Insulin Glargine	Biocon	Apr-17	Jun-20	Aug-20	Additional clinical data requested in support of the manufacturing site change from Bangalore to Malaysia	May-18	Feb-19
						Second CRL	CRL linked to the observations made at the conclusion of the pre-license inspection of the manufacturing facility in Malaysia	Aug-19	Dec-19
Novo Nordisk	Novolog	Insulin Aspart	Sanofi-Aventis	Sep-22	Feb-25	Jul-25	Inadequacy of the proposed endotoxin test method for drug product release	Sep-23	Aug-24
Amgen	Neulasta	Pegfilgrastim	Biocon	Dec-16	Jun-18	Jul-18	Deficiencies relating to the facility and manufacturing	Oct-17	Dec-17
Amgen	Epogen	Epoetin alfa	Pfizer	Dec-14	May-18	Nov-18	Biopotency, immunogenicity and product quality issues	Oct-15	Dec-16
						Second CRL	Manufacturing facility-linked deficiencies	Jun-17	Nov-17
Roche	Herceptin	Trastuzumab	Biocon	Nov-16	Dec-17	Dec-19	Queries related to the update of the application with chemistry, manufacturing, and control (CMC) data after Biocon made plant modifications requiring requalification at its Bangalore facility	NA	NA


Source: Company, Emkay Research

Exhibit 2: Share of oncology in Dr Reddy’s’ global generic sales stood at ~21% in FY26



Source: Company, Emkay Research

Exhibit 3: Price erosion in global generics in FY26 remained in the high single digit



Source: Company, Emkay Research; Note: FY26 price erosion excludes the impact of the US shelf stock adjustment for gRevlimid

Dr Reddy's: Consolidated Financials and Valuations

Profit & Loss

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Revenue	324,269	340,463	370,451	403,750	443,647
Revenue growth (%)	16.2	5.0	8.8	9.0	9.9
EBITDA	85,452	74,772	74,514	87,246	103,212
EBITDA growth (%)	9.0	(12.5)	(0.3)	17.1	18.3
Depreciation & Amortization	17,059	20,607	23,474	25,622	27,973
EBIT	68,393	54,165	51,040	61,625	75,239
EBIT growth (%)	7.6	(20.8)	(5.8)	20.7	22.1
Other operating income	-	-	-	-	-
Other income	3,312	3,964	4,216	4,589	5,035
Financial expense	(4,724)	(4,132)	(4,201)	(5,888)	(7,943)
PBT	76,429	62,261	59,456	72,102	88,217
Extraordinary items	(127)	(7,444)	0	0	0
Taxes	19,056	12,352	14,864	18,025	22,054
Minority interest	(701)	384	288	216	162
Income from JV/Associates	-	-	-	-	-
Reported PAT	56,545	42,849	44,880	54,292	66,325
PAT growth (%)	1.5	(24.2)	4.7	21.0	22.2
Adjusted PAT	56,672	50,293	44,880	54,292	66,325
Diluted EPS (Rs)	68.3	60.6	54.1	65.4	79.9
Diluted EPS growth (%)	1.8	(11.3)	(10.8)	21.0	22.2
DPS (Rs)	8.0	8.0	7.0	8.0	9.0
Dividend payout (%)	11.8	13.2	12.9	12.2	11.3
EBITDA margin (%)	26.4	22.0	20.1	21.6	23.3
EBIT margin (%)	21.1	15.9	13.8	15.3	17.0
Effective tax rate (%)	24.9	19.8	25.0	25.0	25.0
NOPLAT (pre-IndAS)	51,340	43,419	38,280	46,218	56,429
Shares outstanding (mn)	830	830	830	830	830

Source: Company, Emkay Research

Cash flows

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
PBT (ex-other income)	73,117	58,297	55,241	67,513	83,182
Others (non-cash items)	(40,992)	(15,953)	(21,437)	(27,021)	(34,193)
Taxes paid	19,993	13,526	14,864	18,025	22,054
Change in NWC	(18,025)	(15,590)	(10,221)	(11,350)	(13,598)
Operating cash flow	46,428	56,755	57,719	66,901	77,474
Capital expenditure	(105,343)	(48,115)	(35,563)	(38,760)	(42,590)
Acquisition of business	(615)	(862)	0	0	0
Interest & dividend income	-	-	-	-	-
Investing cash flow	(51,021)	(65,513)	(31,362)	(32,872)	(34,647)
Equity raised/(repaid)	368	232	0	0	0
Debt raised/(repaid)	26,746	30,575	(2,000)	(6,000)	(6,000)
Payment of lease liabilities	0	0	0	0	0
Interest paid	4,724	4,132	4,201	5,888	7,943
Dividend paid (incl tax)	(6,662)	(6,659)	(5,810)	(6,640)	(7,470)
Others	(13,321)	(19,990)	(8,276)	(10,329)	(12,823)
Financing cash flow	11,855	8,290	(11,885)	(17,081)	(18,350)
Net chg in Cash	7,262	(468)	14,472	16,948	24,477
OCF	46,428	56,755	57,719	66,901	77,474
Adj. OCF (w/o NWC chg.)	64,453	72,345	67,940	78,251	91,073
FCFF	(58,915)	8,640	22,156	28,141	34,884
FCFE	(61,744)	4,902	17,575	23,801	30,904
OCF/EBITDA (%)	54.3	75.9	77.5	76.7	75.1
FCFE/PAT (%)	(109.2)	11.4	39.2	43.8	46.6
FCFF/NOPLAT (%)	(114.8)	19.9	57.9	60.9	61.8

Source: Company, Emkay Research

Balance Sheet

Y/E Mar (Rs mn)	FY25	FY26	FY27E	FY28E	FY29E
Share capital	834	835	835	835	835
Reserves & Surplus	332,554	376,228	415,298	462,950	521,805
Net worth	333,388	377,063	416,133	463,785	522,640
Minority interests	3,778	3,394	3,106	2,890	2,728
Non-current liab. & prov.	(1,097)	(3,425)	(3,425)	(3,425)	(3,425)
Total debt	46,766	77,341	75,341	69,341	63,341
Total liabilities & equity	382,835	454,373	491,155	532,591	585,284
Net tangible fixed assets	72,924	100,664	110,243	120,300	131,106
Net intangible assets	96,803	105,059	107,570	110,650	114,462
Net ROU assets	-	-	-	-	-
Capital WIP	24,837	15,266	15,266	15,266	15,266
Goodwill	11,810	12,893	12,893	12,893	12,893
Investments [JV/Associates]	4,811	5,673	5,673	5,673	5,673
Cash & equivalents	57,908	87,814	102,286	119,234	143,711
Current assets (ex-cash)	205,388	229,541	248,404	269,350	294,447
Current Liab. & Prov.	91,646	102,537	111,179	120,776	132,274
NWC (ex-cash)	113,742	127,004	137,225	148,575	162,173
Total assets	382,835	454,373	491,155	532,591	585,284
Net debt	(11,142)	(10,473)	(26,945)	(49,893)	(80,370)
Capital employed	382,835	454,373	491,155	532,591	585,284
Invested capital	295,279	345,620	367,930	392,418	420,634
BVPS (Rs)	401.7	454.3	501.4	558.8	629.7
Net Debt/Equity (x)	-	-	(0.1)	(0.1)	(0.2)
Net Debt/EBITDA (x)	(0.1)	(0.1)	(0.4)	(0.6)	(0.8)
Interest coverage (x)	(15.2)	(14.1)	(13.2)	(11.2)	(10.1)
RoCE (%)	21.0	13.8	11.6	12.8	14.3

Source: Company, Emkay Research

Valuations and key Ratios

Y/E Mar	FY25	FY26	FY27E	FY28E	FY29E
P/E (x)	19.9	22.4	25.1	20.7	17.0
P/CE(x)	15.3	15.9	16.5	14.1	11.9
P/B (x)	3.4	3.0	2.7	2.4	2.2
EV/Sales (x)	3.3	3.1	2.9	2.6	2.4
EV/EBITDA (x)	12.5	14.2	14.3	12.2	10.3
EV/EBIT(x)	15.6	19.7	20.9	17.3	14.2
EV/IC (x)	3.6	3.1	2.9	2.7	2.5
FCFF yield (%)	(5.5)	0.8	2.1	2.6	3.3
FCFE yield (%)	(5.5)	0.4	1.6	2.1	2.7
Dividend yield (%)	0.6	0.6	0.5	0.6	0.7
DuPont-RoE split					
Net profit margin (%)	17.5	14.8	12.1	13.4	14.9
Total asset turnover (x)	1.0	0.8	0.8	0.8	0.8
Assets/Equity (x)	1.1	1.2	1.2	1.2	1.1
RoE (%)	18.5	14.2	11.3	12.3	13.4
DuPont-RoIC					
NOPLAT margin (%)	15.8	12.8	10.3	11.4	12.7
IC turnover (x)	1.3	1.1	1.0	1.1	1.1
RoIC (%)	21.0	13.5	10.7	12.2	13.9
Operating metrics					
Core NWC days	128.0	136.2	135.2	134.3	133.4
Total NWC days	128.0	136.2	135.2	134.3	133.4
Fixed asset turnover	1.0	0.8	0.8	0.8	0.8
Opex-to-revenue (%)	32.0	31.6	30.4	30.4	30.2

Source: Company, Emkay Research


This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
13-May-26	1,265	1,200	Reduce	Shashank Krishnakumar
22-Jan-26	1,218	1,200	Reduce	Shashank Krishnakumar
30-Oct-25	1,202	1,100	Reduce	Shashank Krishnakumar
26-Oct-25	1,284	1,200	Reduce	Shashank Krishnakumar
24-Jul-25	1,266	1,150	Reduce	Shashank Krishnakumar
05-Jun-25	1,291	1,050	Reduce	Shashank Krishnakumar
09-May-25	1,156	1,050	Reduce	Shashank Krishnakumar
17-Apr-25	1,164	1,050	Reduce	Shashank Krishnakumar
24-Jan-25	1,224	1,150	Sell	Shashank Krishnakumar
13-Jan-25	1,335	1,150	Sell	Shashank Krishnakumar
06-Nov-24	1,302	1,070	Sell	Shashank Krishnakumar
27-Oct-24	1,303	1,070	Sell	Shashank Krishnakumar

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions)

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of July 01, 2026
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of July 01, 2026
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the July 01, 2026
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for Team White Marque Solutions (team.emkay@whitemarqueresolutions.com)

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)